chevron_leftBack
As of 13 June 2026, Cellid, Co., Ltd. has a market cap of $62.66M USD, ranking #28925 globally and #1565 in South Korea.
It ranks #2624 in the Healthcare sector, and #932 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$62.66MUSD
95.29B KRW
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yuil Kang Chang
open_in_new
Founded
2006
Website
cellid.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.6% | -5% | 25% | -5.8% | -10% | -4.3% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
299660
(주)셀리드 Ordinary Shares
ISIN: KR7299660001
Shares Out.:
Shares Outstanding:
29.503M1
Shares Float:
26.07M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
3,180 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Cellid, Co., Ltd.
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.15B
14K%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.77B
11K%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.24B
8K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.96B
8K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.55B
7K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.44B
7K%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
1M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
873K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
575K%
|
97.4
|
|
SIX: RO
|
$321.52B
513K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
461K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
438K%
218.9B CHF
|
20.5
|
chevron_leftBack